Zepbound for Hair loss

tirzepatide · Investigational / off-label

Last updated 2026-05-28 15:46 UTC

Zepbound (tirzepatide) is not FDA-approved for hair loss, and any use for this condition is off-label or investigational. Research includes a disproportionality analysis linking tirzepatide to alopecia and a cohort study examining new-onset hair loss risk.

AI summary of the sources below.

Drug	Zepbound (tirzepatide)
Condition	Hair loss
Approval status	Investigational / off-label
Research papers	2

Zepbound is not FDA-approved for hair loss; the research below reflects investigational or off-label study only.

Research on tirzepatide for hair loss (2)

Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol · 2025 · 27 citations
Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study. J Am Acad Dermatol · 2026 · 0 citations

Search PubMed ↗